Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.
Researchers from Poseida Therapeutics Inc. presented preclinical data for P-FVIII-101, a novel nonviral gene therapy being developed for the treatment of hemophilia A.
Genmab A/S, in collaboration with Biontech SE, has presented data on a novel OX40 agonist antibody –Hexabody-OX40 (GEN-1055/BNT-315), developed using Genmab’s proprietary Hexabody platform, which promotes the formation of antibody hexamers upon target binding to cell surfaces.
Lowering intraocular pressure (IOP) is still the only approach for treating glaucoma, in which there is mitochondrial damage in the retinal ganglion cells (RGCs). Activating survival pathways in RGCs was thus hypothesized by Indiana University scientists as a strategy for treating glaucoma independently of IOP modulation.
Investigators at Poseida Therapeutics Inc. developed P-KLKB1-101, a nonviral KLKB1 gene editing therapy, being developed for the treatment of hereditary angioedema (HAE).
Researchers from Deutsches Krebsforschungszentrum DKFZ and affiliated organizations presented data for the novel inhibitor of DNA methyltransferase (DNMT) and histone methyltransferase G9a (HMT-G9a), CM-272, being developed for the treatment of acute myeloid leukemia (AML).
Researchers from Fate Therapeutics Inc. presented preclinical data for the multiplexed-engineered, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy, FT-522, as a potential therapeutic against autoimmune diseases.
Kate Therapeutics Inc. recently presented data on a novel muscle- and heart-targeted, liver de-targeted development candidate for the treatment of Duchenne muscular dystrophy (DMD) – KT-809.
HERV-H LTR-associating protein 2 (HHLA2) is known to play immunosuppressive roles by interacting with killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3). The expression of HHLA2 in cancer is associated with poor patient outcomes, making it a promising therapeutic target for immunotherapy. Nextpoint Therapeutics Inc. has presented data on their monoclonal antibodies NPX-267 and NPX-887, which target KIR3DL3 and HHLA2, respectively.
RSS
